151 related articles for article (PubMed ID: 7758054)
41. Persistence of antihypertensive efficacy after missed doses: comparison of amlodipine and nifedipine gastrointestinal therapeutic system.
Elliott HL; Elawad M; Wilkinson R; Singh SP
J Hypertens; 2002 Feb; 20(2):333-8. PubMed ID: 11821720
[TBL] [Abstract][Full Text] [Related]
42. Nifedipine gastrointestinal therapeutic system in stable angina pectoris. Results of a multicenter open-label crossover comparison with standard nifedipine.
Vetrovec GW; Parker VE; Cole S; Procacci PM; Tabatznik B; Terry R
Am J Med; 1987 Dec; 83(6B):24-9. PubMed ID: 3140660
[TBL] [Abstract][Full Text] [Related]
43. Comparison of doxazosin GITS and standard doxazosin in the treatment of high blood pressure.
Os I
Int J Clin Pharmacol Ther; 2006 Mar; 44(3):99-106. PubMed ID: 16550731
[TBL] [Abstract][Full Text] [Related]
44. Effect of telmisartan/hydrochlorothiazide combination versus nifedipine GITS on ambulatory blood pressure and sympathetic activation.
Fogari R; Preti P; Zoppi A; Corradi L; Pasotti C; Rinaldi A; Mugellini A
Am J Hypertens; 2005 May; 18(5 Pt 1):577-83. PubMed ID: 15882537
[TBL] [Abstract][Full Text] [Related]
45. Effectiveness of once-daily monotherapy with a new nifedipine sustained release calcium antagonist.
Carr AA; Bottini PB; Feig P; Prisant LM; Mulligan S; Devane JG; Fisher L; Rhoades RB; MacCarthy EP
Am J Cardiol; 1992 Apr; 69(13):28E-32E. PubMed ID: 1575174
[TBL] [Abstract][Full Text] [Related]
46. Effects of the combination of low-dose nifedipine GITS 20 mg and losartan 50 mg in patients with mild to moderate hypertension.
Kuschnir E; Bendersky M; Resk J; Pañart MS; Guzman L; Plotquin Y; Grassi G; Mancia G; Wagener G
J Cardiovasc Pharmacol; 2004 Feb; 43(2):300-5. PubMed ID: 14716221
[TBL] [Abstract][Full Text] [Related]
47. The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.
Grundy JS; Foster RT
Clin Pharmacokinet; 1996 Jan; 30(1):28-51. PubMed ID: 8846626
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and safety of two different formulations of nifedipine (GITS) vs. slow release microgranules in patients with mild and moderate hypertension.
Botero R; Aroca G; Asa G; González M
J Hum Hypertens; 2002 Mar; 16 Suppl 1():S156-60. PubMed ID: 11986916
[TBL] [Abstract][Full Text] [Related]
49. Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. Doxazosin Investigators' Study Group.
Os I; Stokke HP
J Cardiovasc Pharmacol; 1999 May; 33(5):791-7. PubMed ID: 10226868
[TBL] [Abstract][Full Text] [Related]
50. Once daily nifedipine: the formulation dictates the pharmacokinetic characteristics and the therapeutic responses.
Toal CB; Meredith PA; Elliott HL
Int J Clin Pharmacol Ther; 2012 Mar; 50(3):202-17. PubMed ID: 22373833
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and Safety of Nifedipine Coat-Core versus Amlodipine in Patients With Mild to Moderate Essential Hypertension: Comparison of 24-Hour Mean Ambulatory Diastolic Blood Pressure.
Byyny RL; Shannon T; Schwartz LA; Rotolo C; Jungerwirth S
J Cardiovasc Pharmacol Ther; 1997 Apr; 2(2):77-84. PubMed ID: 10684445
[TBL] [Abstract][Full Text] [Related]
52. Trough:peak ratio of nifedipine gastrointestinal therapeutic system and nifedipine retard in essential hypertensive patients: an Italian multicentre study.
Salvetti A; Virdis A; Taddei S; Ambrosoli S; Caiazza A; Gandolfi E; del Prato C; Saba G; nello Ceccarelli C; Buoninconti R; Spadari G; Kilama MO
J Hypertens; 1996 May; 14(5):661-7. PubMed ID: 8762211
[TBL] [Abstract][Full Text] [Related]
53. Antihypertensive effectiveness of nifedipine gastrointestinal therapeutic system in the elderly. The Modern Approach to the Treatment of Hypertension (MATH) Study Group.
Bravo EL; Krakoff LR; Tuck ML; Friedman CP
Am J Hypertens; 1990 Dec; 3(12 Pt 2):326S-332S. PubMed ID: 2078319
[TBL] [Abstract][Full Text] [Related]
54. Ambulatory blood pressure profiles in essential hypertensives after treatment with a new once daily nifedipine formulation.
Nold G; Herholz C; Sturm M; Hopf R; Lemmer B
J Hum Hypertens; 1999 Mar; 13(3):173-7. PubMed ID: 10204813
[TBL] [Abstract][Full Text] [Related]
55. Conversion from sustained-release to immediate-release calcium entry blockers: outcome in patients with mild-to-moderate hypertension.
Hilleman DE; Mohiuddin SM; Lucas BD; Shinn B; Elsasser GN
Clin Ther; 1993; 15(6):1002-10. PubMed ID: 8111798
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
[TBL] [Abstract][Full Text] [Related]
57. Nifedipine GITS replacing nifedipine SR: ambulatory blood pressure assessment of efficacy.
Rahima-Maoz C; Grossman E; Nussinovitch N; Katz A; Rosenthal T
Cardiology; 1997; 88 Suppl 3():43-6. PubMed ID: 9397293
[TBL] [Abstract][Full Text] [Related]
58. Doxazosin GITS versus standard doxazosin in mild to moderate hypertension.
Calvo C; Gil-Extremera B; Gomez-Fernández P; Masramon X; Pueyo C; Armada B
Int J Cardiol; 2005 May; 101(1):97-104. PubMed ID: 15860390
[TBL] [Abstract][Full Text] [Related]
59. Fixed-dose combination of nifedipine gastrointestinal therapeutic system and candesartan cilexetil in patients with moderate-to-severe essential hypertension: an open-label, long-term safety and efficacy study.
Kjeldsen SE; Dzongowski P; Li N; Wang L; Radlmaier A
J Clin Pharm Ther; 2016 Dec; 41(6):695-702. PubMed ID: 27670639
[TBL] [Abstract][Full Text] [Related]
60. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia.
Andersen M; Dahlstrand C; Høye K
Eur Urol; 2000 Oct; 38(4):400-9. PubMed ID: 11025377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
